Worth reading
55In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-142
¥ millions (year-on-year change in operating income)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Presentation materials on financial resultsFirst quarter of the fiscal year ending December 20269 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥916 million-20.4%
Operating profit¥-98 million
Ordinary income¥-93 million
Net income¥-95 million
Gross Profit Margin54.6%
Operating profit margin-10.7%
Selling, general and administrative expenses¥598 million
Results for the three months of the current quarter
Net Sales
¥916 million
Full-year earnings forecast
Net Sales
¥7,200 million
Pharmaceuticals revenue
¥6,695 million
Infection control revenue
¥500 million
Other net sales
¥5 million
Operating profit
¥500 million
Ordinary income
¥520 million
Net income for the current fiscal year
¥550 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Lower revenue from the pharmaceuticals business¥-54 million
- Lower revenue from the infection control business¥-59 million
- Cost impact¥-75 million
- Foreign Exchange Effects¥7 million
- Selling, general and administrative expenses¥36 million
- Other¥2 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
The possibility of production disruptions due to soaring material prices and procurement delays has been indicated, but the numerical assumptions are Not disclosedNew initiatives
- Concentrating investment in the pharmaceuticals business
- Expanding Seirogan supply from the second half onward
- Strengthening promotion of the Seirogan brand during the summer demand season
- Strengthening efforts to develop new domestic business-use customers
Key KPIsA metric the company considers important as a management benchmark.
- Domestic antidiarrheal market size¥2,948 million
- Taiko Pharmaceutical share44 %
Segment results
- Pharmaceuticals BusinessNet Sales¥858 million (YoY -13.2%)Segment Profit or Loss¥160 million (YoY -49.0%)
- Infection-Control BusinessNet Sales¥56 million (YoY -64.6%)Segment Profit or Loss¥-41 million
- Other BusinessesNet Sales¥1 million (YoY +2.9%)Segment Profit or Loss¥-5 million
Medium-term management plan targets
The medium-term management plan for 2026–2028 is mentioned, but the target figures are Not disclosedFinancial targets
Equity ratio
73 %
Market Size / Share
Market Size
¥2,948 million
Taiko Pharmaceutical share
44 %
Capital expenditures
¥40 millions research and development expenses
| Item | Details |
|---|---|
| Document type | Presentation materials on financial results |
| Fiscal Period Covered | First quarter of the fiscal year ending December 2026 |
| Net Sales | ¥916 million (YoY -20.4%) |
| Operating profit | ¥-98 million |
| Ordinary income | ¥-93 million |
| Net income | ¥-95 million |
| Gross Profit Margin | 54.6% |
| Operating profit margin | -10.7% |
| Selling, general and administrative expenses | ¥598 million |
| Results for the three months of the current quarter | Net Sales ¥916 million |
| Full-year earnings forecast | Net Sales ¥7,200 million / Pharmaceuticals revenue ¥6,695 million / Infection control revenue ¥500 million / Other net sales ¥5 million / Operating profit ¥500 million / Ordinary income ¥520 million / Net income for the current fiscal year ¥550 million |
| Segment results | Segment Pharmaceuticals Business / Net Sales ¥858 million (YoY -13.2%) / Segment Profit or Loss ¥160 million (YoY -49.0%), Segment Infection-Control Business / Net Sales ¥56 million (YoY -64.6%) / Segment Profit or Loss ¥-41 million, Segment Other Businesses / Net Sales ¥1 million (YoY +2.9%) / Segment Profit or Loss ¥-5 million |
| Breakdown of Factors Affecting the Change | Factors Lower revenue from the pharmaceuticals business / Amount ¥-54 million, Factors Lower revenue from the infection control business / Amount ¥-59 million, Factors Cost impact / Amount ¥-75 million, Factors Foreign Exchange Effects / Amount ¥7 million, Factors Selling, general and administrative expenses / Amount ¥36 million, Factors Other / Amount ¥2 million |
| Key KPIs | Indicator name Domestic antidiarrheal market size / Value ¥2,948 million / Year on year against the same period last year Not disclosed, Indicator name Taiko Pharmaceutical share / Value 44 % / Year on year against the same period last year Not disclosed |
| Assumptions Underlying the Business Outlook | The possibility of production disruptions due to soaring material prices and procurement delays has been indicated, but the numerical assumptions are Not disclosed |
| Medium-term management plan targets | The medium-term management plan for 2026–2028 is mentioned, but the target figures are Not disclosed |
| Financial targets | Equity ratio 73 % |
| Capital expenditures | ¥40 millions (research and development expenses) |
| Market Size / Share | Market Size ¥2,948 million / Taiko Pharmaceutical share 44 % |
| New initiatives | Concentrating investment in the pharmaceuticals business, Expanding Seirogan supply from the second half onward, Strengthening promotion of the Seirogan brand during the summer demand season, Strengthening efforts to develop new domestic business-use customers |
Items this document does not state (11)
Progress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue declined due to reduced Seirogan supply, the resumption of supply of competing products, lower inbound demand, and market contraction following the influenza outbreak. In addition, higher costs associated with strengthening the supply system and increased costs resulting from a temporary decline in yield put downward pressure on operating income.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.